It seems you are looking for a specific technical report (likely from the 1980s or early 1990s) regarding PDA — which in that context probably means Personal Digital Assistant (early devices like the Apple Newton, Psion Series 3, or Palm) — with the identifier “Technical Report 82”.

However, “PDA Technical Report 82” is not a globally standard or uniquely identifiable document title. Several possibilities exist:

  1. University Technical Report Series
    Many computer science departments (e.g., Stanford, Carnegie Mellon, University of Cambridge) published internal technical reports numbered 82.

    • Example: “TR-82: A Prototype Personal Digital Assistant with Pen-Based Input” from a university lab in the late 1980s.
    • Without the institution name, it’s difficult to retrieve.

  2. Company Internal Report
    Companies like Psion, Apple, USRobotics (Palm), or HP might have used “TR-82” internally.

    • For instance, Psion’s R&D published a series of “Technical Reports” during the development of the Series 3 PDA.
    • Such reports are not publicly archived in digital libraries.

  3. Possible Confusion with “IEEE 82” or “ISO/IEC TR 82”
    No known ISO or IEEE technical report #82 relates to PDAs.

    • ISO/IEC TR 82 (if it existed) might be about something else (e.g., programming languages, databases).

  4. Academic Paper Citing TR-82
    You may have seen a citation like:

    (PDA Technical Report 82, 1992)
    in a bibliography of a later paper on mobile computing or pen-based interfaces.
    Searching Google Scholar for "Technical Report 82" PDA sometimes reveals the citing paper, which may include the full title and authors.

Decoding Low Endotoxin Recovery: A Comprehensive Guide to PDA Technical Report 82

In the world of parenteral drug manufacturing, ensuring sterility and safety is paramount. While the compendial bacterial endotoxins test (BET), often regulated by USP <85> and EP 2.6.14, has been the gold standard for decades, the industry has faced a perplexing and potentially dangerous phenomenon: Low Endotoxin Recovery (LER) .

For years, LER was a poorly understood anomaly where endotoxin activity appeared to diminish or "disappear" in certain drug product matrices over time, even though the endotoxin was physically present. This created a regulatory blind spot, as standard QC testing could produce false negatives.

Enter PDA Technical Report 82 (TR 82) , titled "Low Endotoxin Recovery". Published by the Parenteral Drug Association (PDA) in 2018, this document is the most authoritative, comprehensive resource for understanding, investigating, and mitigating LER. This article provides a deep dive into TR 82, its findings, methodologies, and its impact on the biopharmaceutical industry.

3. Risk-Based Assessment

Not all products are at equal risk. TR 82 provides a decision tree to classify risk:

4. Validation and Implementation Strategy

TR 82 outlines a structured approach to validating a trickle sterilization process. This is the "how-to" section of the document and is critical for Quality Assurance and Validation teams.

Step 1: Risk Assessment Before implementing, a formal risk assessment (e.g., FMEA – Failure Mode and Effects Analysis) must be conducted to identify potential failure points, such as cold spots, dead legs, or pump overheating due to low flow.

Step 2: Thermal Mapping This is the most critical step. Unlike a standard system where one temperature probe might suffice, trickle sterilization requires multiple thermocouples placed at:

Step 3: Cycle Development Operators must define the parameters:

Step 4: Microbiological Monitoring Post-sanitization monitoring must be rigorous. The report suggests enhanced sampling immediately following the implementation of trickle sterilization to verify that microbial counts remain below action limits (e.g., < 10 CFU/100mL for Purified Water).

Conclusion

PDA TR-82 is an essential resource for quality control microbiologists, formulation scientists, and regulatory affairs professionals working with complex parenterals. It shifted the industry’s mindset from assuming endotoxin is stable and fully recoverable to recognizing that matrix effects can hide endotoxin activity. Implementing TR-82 guidance reduces the risk of releasing a pyrogenic product that passes the BET—a critical step toward safer sterile pharmaceuticals.

Reference
PDA. Technical Report No. 82 (2018): Low Endotoxin Recovery. Bethesda, MD: Parenteral Drug Association.

PDA Technical Report No. 82 (TR 82) serves as the industry standard for investigating Low Endotoxin Recovery (LER) in biologics, guiding manufacturers on evaluating potential false-negative endotoxin tests. Published in 2019, the report dictates specific methodologies for hold-time studies and is widely accepted by regulatory bodies like the FDA and EMA. While recognized as the benchmark for compliance, the Parenteral Drug Association (PDA) is currently revising the document to address challenges in execution and scientific advancements. For more details, visit the Parenteral Drug Association www.linkedin.com Alessandro Pauletto - European Medicines Agency (EMA)

A Comprehensive Review of PDA Technical Report 82: A Guideline for Pharmaceutical and Biotechnology Industries

The Parenteral Drug Association (PDA) is a renowned organization that provides guidance and resources for the pharmaceutical and biotechnology industries. One of its notable publications is Technical Report 82 (TR 82), which focuses on the evaluation of sterile compounding facilities. In this article, we will provide an in-depth review of PDA Technical Report 82, its significance, and its implications for the pharmaceutical and biotechnology industries.

Introduction

The pharmaceutical and biotechnology industries are highly regulated, with strict guidelines and standards in place to ensure the quality and safety of products. One critical aspect of these industries is the compounding of sterile preparations, which requires specialized facilities and equipment to prevent contamination. PDA Technical Report 82 provides a comprehensive guide for evaluating sterile compounding facilities, helping organizations ensure compliance with regulatory requirements.

Background

The PDA first published Technical Report 82 in 2015, with the aim of providing a detailed framework for evaluating sterile compounding facilities. The report was developed by a team of experts with extensive experience in sterile compounding, facility design, and regulatory compliance. TR 82 provides guidance on the key elements of sterile compounding facilities, including design, construction, and operation.

Key Components of PDA Technical Report 82

TR 82 is divided into several sections, each addressing a critical aspect of sterile compounding facilities. The report covers the following key components:

  1. Facility Design: The report provides guidance on the design of sterile compounding facilities, including layout, materials, and finishes. It emphasizes the importance of a well-designed facility in preventing contamination and ensuring product quality.
  2. Environmental Controls: TR 82 discusses the environmental controls necessary for sterile compounding, including temperature, humidity, and air quality. It provides recommendations for the design and operation of heating, ventilation, and air conditioning (HVAC) systems.
  3. Equipment and Instrumentation: The report covers the equipment and instrumentation required for sterile compounding, including laminar flow hoods, glove boxes, and sterility testing equipment.
  4. Cleaning and Disinfection: TR 82 provides guidance on cleaning and disinfection procedures for sterile compounding facilities, including the selection of cleaning agents and disinfectants.
  5. Quality Control and Quality Assurance: The report emphasizes the importance of quality control and quality assurance (QC/QA) programs in sterile compounding facilities. It provides recommendations for QC/QA procedures, including testing and validation.

Significance of PDA Technical Report 82

PDA Technical Report 82 is significant for several reasons:

  1. Regulatory Compliance: TR 82 provides guidance on regulatory requirements for sterile compounding facilities, helping organizations ensure compliance with FDA, EMA, and other regulatory agencies.
  2. Patient Safety: By ensuring the quality and safety of sterile compounded products, TR 82 contributes to patient safety and well-being.
  3. Industry Best Practices: The report provides a framework for industry best practices in sterile compounding, helping organizations optimize their facilities and operations.
  4. Facilitating Inspections and Audits: TR 82 provides a reference for inspectors and auditors, facilitating the evaluation of sterile compounding facilities.

Implications for the Pharmaceutical and Biotechnology Industries

The implications of PDA Technical Report 82 are far-reaching:

  1. Investment in Facility Design and Construction: Organizations may need to invest in the design and construction of new facilities or renovate existing ones to comply with TR 82 guidelines.
  2. Enhanced Quality Control and Quality Assurance: TR 82 emphasizes the importance of QC/QA programs, which may require significant investments in personnel, equipment, and procedures.
  3. Training and Education: Organizations must ensure that personnel are trained and educated on the principles and guidelines outlined in TR 82.
  4. Regulatory Preparedness: Organizations must be prepared for regulatory inspections and audits, which may focus on compliance with TR 82 guidelines.

Conclusion

PDA Technical Report 82 is a comprehensive guide for evaluating sterile compounding facilities. Its significance extends beyond regulatory compliance, contributing to patient safety and industry best practices. The implications of TR 82 are far-reaching, requiring organizations to invest in facility design and construction, enhance quality control and quality assurance, provide training and education, and ensure regulatory preparedness. As the pharmaceutical and biotechnology industries continue to evolve, TR 82 will remain a critical resource for ensuring the quality and safety of sterile compounded products.

Recommendations

Based on the guidelines outlined in TR 82, we recommend the following:

  1. Conduct a thorough evaluation of sterile compounding facilities to ensure compliance with TR 82 guidelines.
  2. Develop and implement a comprehensive QC/QA program to ensure the quality and safety of sterile compounded products.
  3. Provide training and education for personnel on the principles and guidelines outlined in TR 82.
  4. Regularly review and update facility design, construction, and operations to ensure ongoing compliance with TR 82 guidelines.

By following these recommendations, organizations can ensure compliance with regulatory requirements, contribute to patient safety, and maintain industry best practices in sterile compounding.

PDA Technical Report 82 (TR 82), "Low Endotoxin Recovery," provides a crucial, internationally recognized framework for managing endotoxin masking in biologic drugs, specifically guiding Hold Time Studies. The 2019 report addresses how formulation components, such as surfactants, can inhibit LAL test detection, with active industry discussions ongoing regarding a future revision. For more details on the upcoming workshop, visit Parenteral Drug Association PDA Pharmaceutical Manufacturing & Quality Conference 2025

Since the publication of PDA TR 82 in 2019, there have been significant industry effort to understand the Low Endotoxin Recovery ( Parenteral Drug Association PDA Pyrogens Workshop 2025 - Parenteral Drug Association

It sounds like you’re looking for a specific feature, table, figure, or section from PDA Technical Report No. 82 (TR-82), titled “Low Endotoxin Recovery” (published 2020).

However, your request is quite broad. To give you the exact feature you need, please clarify which of the following you’re referring to:

  1. A specific figure or table (e.g., "Figure 3.1 showing LER timeline" or "Table of root causes")
  2. A key procedural feature (e.g., "dilution neutralization step," "use of rFC vs. LAL," "sample handling time limits")
  3. A feature of the LER phenomenon (e.g., "masking vs. binding," "recovery vs. time profile")
  4. A feature of the recommended control strategy (e.g., "routine spiking," "sample storage conditions")

If you can provide more detail (e.g., “I need the feature regarding sample storage temperature” or “the feature showing recovery drop vs. container type”), I can locate that exact content from TR-82 for you.

Alternatively, if you’re asking for a summary of the most critical feature of TR-82, it’s this:

Key Feature of PDA TR-82: Endotoxin can become undetectable (low/no recovery) in certain matrices over time even when spiked, not due to degradation but due to masking, aggregation, or adsorption — and this loss of detection can be reversed by appropriate sample treatment (e.g., dilution, heating, or surfactant addition).

Just let me know which specific feature you need, and I’ll give you the precise details.

2. Core Definitions and Concepts

Turbulent Flow (The Standard): Regulatory guidelines (like those from the FDA and EMA) and pharmacopeial standards often implicitly assume turbulent flow is necessary to scour biofilm and ensure heat distribution. This is usually defined by a Reynolds number greater than 10,000.

Trickle Sterilization (The Alternative): TR 82 defines this as a thermal sanitization process performed at flow rates significantly lower than those required for turbulent flow (often approaching laminar flow regimes, e.g., Reynolds numbers < 4,000). The primary mechanism for sanitization here is thermal kill (time-temperature lethality) rather than mechanical removal via shear force.